Clicky

Ameri Holdings, Inc.(ENVB) News

Date Title
Jul 25 Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
Jun 25 Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
May 30 Enveric Biosciences to Participate in BIO International Convention 2024
May 15 Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
May 14 Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
May 8 Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
Mar 26 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Mar 19 Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
Mar 12 Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
Dec 29 Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
Dec 28 Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
Dec 27 Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
Dec 20 Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"
Dec 5 Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
Nov 29 Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
Nov 27 Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
Sep 27 Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
Jul 17 Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
May 2 Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month